Concourse Financial Group Securities, Inc. Monte Rosa Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 100.0%

18 transactions

Quarter	Operation	Price Per share
Q2 2025 Aug 12, 2025	BUY	$3.7 - $5.33 $0 - $0
Q1 2025 May 14, 2025	BUY	$4.64 - $7.17 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$4.8 - $10.36 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$3.59 - $6.97 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$3.38 - $7.86 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$4.26 - $8.46 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$2.5 - $5.93 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$4.78 - $7.22 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$4.78 - $7.22 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$4.53 - $8.4 $0 - $0
Q1 2023 May 15, 2023	BUY	$5.95 - $8.21 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$6.71 - $9.72 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$7.17 - $12.16 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$6.15 - $14.99 $0 - $0
Q1 2022 May 09, 2022	BUY	$10.36 - $20.41 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$16.28 - $27.15 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$18.59 - $42.21 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$18.86 - $22.7 $0 - $0

Others Institutions Holding GLUE

# of Institutions

116

Shares Held

58M

Call Options Held

56.3K

Put Options Held

Nea Management Company, LLC Timonium, MD

7.69M
Shares

$104 Million
2.88% of portfolio
Price T Rowe Associates Inc Baltimore, MD

6.33M
Shares

$85.6 Million
0.0% of portfolio
Bvf Inc San Francisco, CA

5.66M
Shares

$76.6 Million
1.0% of portfolio
Versant Venture Management, LLC San Francisco, CA

5.65M
Shares

$76.5 Million
68.34% of portfolio
Baker Bros. Advisors LP New York, NY

4.92M
Shares

$66.6 Million
0.22% of portfolio

View Full List

About Monte Rosa Therapeutics, Inc.

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $633M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

More about GLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account